-$1.15 EPS Expected for GALAPAGOS NV/S (GLPG) This Quarter

Equities analysts expect that GALAPAGOS NV/S (NASDAQ:GLPG) will report earnings per share of ($1.15) for the current quarter, Zacks reports. Five analysts have made estimates for GALAPAGOS NV/S’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($1.66). GALAPAGOS NV/S posted earnings of ($0.50) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 130%. The firm is expected to report its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that GALAPAGOS NV/S will report full year earnings of ($4.77) per share for the current financial year, with EPS estimates ranging from ($6.40) to ($3.91). For the next year, analysts anticipate that the firm will report earnings of ($5.30) per share, with EPS estimates ranging from ($8.06) to ($3.77). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover GALAPAGOS NV/S.

A number of analysts have weighed in on GLPG shares. Zacks Investment Research raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Tuesday, January 8th. BidaskClub raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a report on Friday, January 11th. ValuEngine cut shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. Svb Leerink started coverage on shares of GALAPAGOS NV/S in a report on Friday, February 22nd. They set an “outperform” rating on the stock. Finally, Leerink Swann started coverage on shares of GALAPAGOS NV/S in a report on Friday, February 22nd. They set an “outperform” rating and a $140.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $127.27.

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new stake in GALAPAGOS NV/S during the 3rd quarter valued at about $399,000. BlackRock Inc. grew its stake in GALAPAGOS NV/S by 18.4% during the 3rd quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after acquiring an additional 56,848 shares in the last quarter. Morgan Stanley grew its stake in GALAPAGOS NV/S by 10.8% during the 3rd quarter. Morgan Stanley now owns 79,319 shares of the biotechnology company’s stock valued at $8,917,000 after acquiring an additional 7,752 shares in the last quarter. Marshall Wace North America L.P. grew its stake in GALAPAGOS NV/S by 258.1% during the 3rd quarter. Marshall Wace North America L.P. now owns 23,994 shares of the biotechnology company’s stock valued at $2,697,000 after acquiring an additional 17,294 shares in the last quarter. Finally, Federated Investors Inc. PA grew its stake in GALAPAGOS NV/S by 17.8% during the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock valued at $188,648,000 after acquiring an additional 253,159 shares in the last quarter. Institutional investors and hedge funds own 15.87% of the company’s stock.

Shares of NASDAQ:GLPG traded up $2.27 on Wednesday, reaching $115.98. 90,254 shares of the company’s stock were exchanged, compared to its average volume of 110,779. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $125.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.31 and a quick ratio of 6.31.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: What Are Treasury Bonds?

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.